Harrison, C., Kiladjian, J.J., Al-Ali, H.K., et al. (2012) JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis. The New England Journal of Medicine, 366, 787-798.
https://doi.org/10.1056/NEJMoa1110556

has been cited by the following article:

• TITLE: Advances in the Study of High-Risk Gene Mutations for Primary Myelofibrosis

  AUTHORS: Shaoming Xu, Youshan Zhang, Jie Tan, Caixia Liang

  KEYWORDS: Primary Myelofibrosis, High-Risk Mutations, Myeloproliferative Neoplasms

  JOURNAL NAME: Journal of Biosciences and Medicines, Vol.10 No.7, July 8, 2022

  ABSTRACT: Primary myelofibrosis is a kind of MPNs due to clonal appreciation of hematopoietic stem cells. With the development of second-generation sequencing, high-risk mutation (HMR) genes such as ASXL1, EZH2, SRSF2, and IDH1/2 have been shown to be associated with disease prognosis and progression, and although allo-HSCT remains the only possible treatment for PMF, with the development of JAK inhibitors, there is an increasing interest in the study of inhibitors of these mutant loci.